USP, government labs to launch drug quality network; GSK adds solar panels in RTP;

> The United States Pharmacopeial Convention and six government drug control labs in the Middle East and Northern Africa have joined to launch a drug quality improvement network. Article

> GlaxoSmithKline is preparing to install more solar panels at its Research Triangle Park campus. Item

> One-third of those polled say they are not sure if their company's CAPA system is robust enough to withstand a regulatory inspection. Release

> Officials in China believe they may have found the facility used to make counterfeits of Roche's Avastin. Article

> Cangene answers questions about its conversion to an electronic system for managing the training of plant workers. Interview

> Capillary electrophoresis machines are ready for installation in Cambodia and Congo, part of a European initiative to use the low-cost, easy to operate gear to analyze commonly counterfeited medicines. Article

> Material costs for plastic bottles and blister packs have risen by double-digit percentages over the past two years. Release

> Officials have approved a plan for connecting a Merck facility with the local water treatment plant to accommodate 300,000 gallons per day, about one-third of the West Point, PA, plant's wastewater. News

> Canada's Paralympic gold medal-winning curling team captain has pleaded guilty in the U.S. to selling counterfeit erectile-dysfunction drugs. Article

> Albania is setting up a pharmacovigilance center to monitor undesirable drug effects and develop measures for their prevention. Story

> Microscan has unveiled VS-1 Track and Trace, a solution for inspecting and verifying package label content. Microscan release

Suggested Articles

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.